MarketPulse

European Commission approval

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Chiesi Global Rare Diseases / Protalix Biotherapeutics

Elfabrio Wins EU Approval for Less-Frequent Dosing, Triggering $25M Payment

European Commission approves every-4-weeks dosing regimen for Elfabrio, reducing patient treatment burden and triggering $25 million milestone payment to Protalix from Chiesi.
PLXrare diseaseEuropean Commission approval
BenzingaBenzinga··Vandana Singh

European Regulators Approve GSK's Biannual Asthma Drug Targeting Type 2 Inflammation

European regulators approve GSK's Exdensur, a biannual asthma injection targeting type 2 inflammation. The drug also treats chronic rhinosinusitis with nasal polyps, showing significant exacerbation reductions in trials.
GSKPhase 3 trialssevere asthma